Stem Cell Research and Application in Diabetes Treatment

Stem Cell Research and Application in Diabetes Treatment

Current Status of Research

  • Stem cells have not yet reached full clinical readiness for widespread use.

  • Ongoing project using human donor cells for diabetes treatment due to their availability.

Experimental Procedure Overview

  • Subject Models: Diabetic mice and rats with elevated blood sugar levels (400-500 mg/dL).

  • Transplantation Method: Administration of a small amount of bile results in immediate blood sugar reduction to below 200 mg/dL.

Experimental Results

  • Conducted tests on approximately 30 different mouse models, represented by three squiggly lines (yellow and blue).

  • Mice show sustained health and functionality for up to 200 days post-treatment; aging of mice evaluated by age at 200 days.

  • Similar experiments conducted on rats, which are known to have a stronger immune response compared to mice.

Historical Context of Diabetes Research in Canada

  • Canada has a rich history in diabetes research:

    • Discovery of Insulin: Occurred approximately 102 years ago in Canada.

    • Stem Cells Discovery: Also linked to Canadian research; critical advances made in Toronto.

    • Edmonton Protocol Development: Developed in Canada, it details the transplantation of human donor islets into Type 1 diabetics under immune suppression.

Objectives and Innovations

  • Aim to eliminate the need for immune suppression in islet transplants, representing a significant advancement in diabetes treatment.

  • Current research has demonstrated efficacy in animal models (mice and rats).

Clinical Trial Plans

  • Proposed clinical trial details:

    • Involvement of two partnering organizations.

    • Anticipation of six patients participating, structured as a single-arm trial (all patients receive treatment, no placebos).

    • Ethical considerations: It is not sustainable to have a placebo group due to the nature of diabetes treatment efficacy. Every participant will know whether they receive actual islets.

    • Trial is scheduled to begin next year, aiming to expand the patient treatment pool significantly without the constraints of immune suppression.

Team Composition

  • Growth of the research company to around 30 employees.

  • Composition of team includes:

    • Polymer Chemists: Developing gel forms for implantation.

    • Engineers: Designing the necessary medical devices for implantation.

    • Cell Biologists: Overseeing the viability and health of cells before and after transplantation.

    • Animal Care Team: Responsible for animal support during experiments and trials.

  • Additional backing from a board of directors and a scientific advisory board that poses critical questions and provides support.

Current Diabetes Management Landscape

  • Conventional Pathology: Present solutions include artificial device pumps and sensor combinations.

    • Image referenced from the Juvenile Diabetes Research Foundation (JDRF), a significant foundation working towards Type 1 diabetes cures.

  • Advancing towards Cell Therapy: Emphasis on cell therapy to restore natural pancreatic function for Type 1 diabetics.

Development Process for New Treatments

  • Key elements necessary for successful translation from research to clinical outcomes:

    • Identification of a niche idea in the field of diabetes treatment; immune suppression challenges in islet transplantation prompted research.

    • Recruitment of People: Initial team members included a PhD student and others, establishing the foundational core group.

    • Facility Considerations: Accessing adequate university lab space for research activities.

    • Insurance Needs: Transitioning from university affiliation involves obtaining necessary insurance coverage.

    • Funding Strategies: Seeking both dilutive (equity investment) and nondilutive funding (grants).

    • Investors want a compelling story backed by solid initial data and demonstrated growth potential.

    • Collaborative Partnerships: Developing relationships with major pharmaceutical companies, leading to possible licensing agreements for product distribution.

Steps in Product Development

  • Data generation and validation are essential.

  • Protecting intellectual property rights early in the process is critical for commercial viability.

  • Engagement with pharmaceutical partners for product development and commercialization.

  • The process of development is cyclical; multiple iterations are necessary.

Conclusion

  • Strong emphasis placed on collaboration and comprehensive planning as crucial aspects of advancing diabetes treatments through innovative methodologies.

  • The speaker expresses gratitude to the audience for attention and engagement.